1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)

Saved in:
Bibliographic Details
Published in:Immuno-oncology technology 2022-12, Vol.16, p.100106, Article 100106
Main Authors: Felip, E., Srivastava, M., Reck, M., Wakelee, H., Altorki, N.K., Vallieres, E., Liersch, R., Harada, M., Tanaka, H., Hamm, J.T., McCune, S., Bennett, E., Gitlitz, B.J., McNally, V.A., Novello, S., Ballinger, M., Zou, W., Nabet, B., Das Thakur, M., Zhou, C.
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2590-0188
2590-0188
DOI:10.1016/j.iotech.2022.100106